title: Calcium blockers: antiatherogenic action by influencing the prostaglandin-system.
authors.affiliation: Atherosclerosis Research Group, Vienna, Austria.
authors.forename: K
authors.initials: K
authors.lastname: Weiss
authors.forename: P
authors.initials: P
authors.lastname: Fitscha
authors.forename: A
authors.initials: A
authors.lastname: Gazsó
authors.forename: D
authors.initials: D
authors.lastname: Gludovacz
authors.forename: H
authors.initials: H
authors.lastname: Sinzinger
mesh_terms: D000328:Adult; D000818:Animals; D001161:Arteriosclerosis / Q000517:prevention & control*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D004110:Diltiazem / Q000494:pharmacology; D011464:Epoprostenol / Q000096:biosynthesis; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D017275:Isradipine; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D009543:Nifedipine / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D011453:Prostaglandins / Q000502:physiology*; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D014700:Verapamil / Q000494:pharmacology
chemical_list: D002121:Calcium Channel Blockers; D011453:Prostaglandins; D011725:Pyridines; D008315:Malondialdehyde; D014700:Verapamil; D011464:Epoprostenol; D004110:Diltiazem; D009543:Nifedipine; D017275:Isradipine